GSK
Last updated Jun 16, 2026
Evidence Sources
7
Competitive Findings
0
Portfolio Developments
2
Regulatory Precedents
6
Clinical Programs
0
Confidence Coverage
84%
Audit
- Competitor findings: 0
- Portfolio developments: 2
- Self-competition findings removed: 2
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Infectious Disease
- Pneumococcal Vaccine
- Influenza
- Psychiatry
- PTSD
Highest priority development: Pfizer's 25vPnC Vaccine Shows Strong Phase 2 Results, Advancing to Phase 3
Portfolio development
Pfizer's 25vPnC Vaccine Shows Strong Phase 2 Results, Advancing to Phase 3 is an owned GSK portfolio development in Infectious Disease · Pneumococcal Vaccine.
Competitive pressure: Low
Portfolio impact: High
Evidence coverage: 84%
Active Signals
3
Investigate Priority
1
Opportunity Score
83
Buyer Quality
10 · Enterprise
Recent Signals
Latest intelligence events linked to this organization.
- InvestigateJun 16, 2026Score 31Pfizer's 25vPnC Vaccine Shows Strong Phase 2 Results, Advancing to Phase 3
Infectious Disease · Pneumococcal Vaccine
- MonitorJun 14, 2026Score 26GSK's AS03-adjuvanted H5N8 vaccine shows promising immunogenicity and safety in Phase 1/2 trial
Infectious Disease · Influenza
- MonitorJun 10, 2026Score 26Study Compares PE Therapy, Pharmacotherapy, and Combination for PTSD in Veterans
Psychiatry · PTSD
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
- Low Confidence · 0%Sources (3)Humanexa SignalsPfizerPortfolio
- Low Confidence · 0%Sources (3)PubMedPfizerPortfolio
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- October - December 2022 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)Moderate Confidence · 84%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - July - September 2022 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)Moderate Confidence · 84%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - January - March 2022 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)Moderate Confidence · 84%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
- InvestigateScore 31Pfizer's 25vPnC Vaccine Shows Strong Phase 2 Results, Advancing to Phase 3
Infectious Disease · Pneumococcal Vaccine
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to GSK right now?
- Which regulatory precedents should GSK monitor in Infectious Disease and Pneumococcal Vaccine?
- How does Emerging Vaccine and Treatment Strategies in Infectious Disease Landscape compare to the nearest competitive programs?
- What signals require immediate investigation for GSK?
- Summarize the strategic implications of recent developments for GSK.
- Where is the greatest uncertainty in GSK's competitive positioning?